New drug DS-1062a tested in humans for first time against advanced cancers
NCT ID NCT03401385
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 23 times
Summary
This study tests a new drug called DS-1062a in people with advanced solid tumors, including certain lung and breast cancers that have not responded to standard treatments. It is the first time this drug is being used in humans, and the main goals are to check its safety and find the best dose. About 890 participants will take part, and those who benefit may continue treatment unless side effects become too severe or the disease worsens.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Nagoya, Aichi-ken, 464-8681, Japan
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Johns Hopkins Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital
Chūōku, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa, 277-8577, Japan
-
Next Oncology
San Antonio, Texas, 78229, United States
-
START Oncology
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37205, United States
-
Showa Medical University Hospital
Shinagawa-Ku, Tokyo, 142-0064, Japan
-
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Koto-Ku, Tokyo, 135-8550, Japan
-
Tisch Cancer Institute, Icahn School of Medicine
New York, New York, 10029, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.